Samsara Vision (SMSA) Files IPO Registration Statement
- Stocks, oil higher as China relaxes quarantine rules
- Earnings Estimates are 'Likely Too Optimistic', Risk Not Fully Reflected - Goldman
- Bank of America Clients are Selling This Rally
- Nike (NKE) Drops After Results, Morgan Stanley Positive After 'Reset' Quarter
- FTX-Robinhood Rumors: Piper Sandler Sees a 'Win-win' Situation, Others Less Optimistic
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Samsara Vision (NASDAQ: SMSA) files IPO registration statement.
The company describes itself as: "We are a specialty medical device company dedicated to bringing vision and freedom back to patients suffering from late-stage conditions of the retina. We are engaged in the research, development, manufacturing, and marketing of proprietary ophthalmic devices and technologies that are intended to significantly improve vision and quality of life for individuals with untreatable retinal disorders, particularly Age-Related Macular Degeneration (“AMD”).
Eye health markets are some of the most lucrative and growing markets in the health care sector today. In addition, we believe that within the eye health market, the retinal disease market is among the most valuable, as it features an area of great unmet need.
BrightFocus Foundation estimates that the number of individuals world-wide diagnosed with AMD is expected to grow to 288 million by the year 2040. While treatments focus on the neovascular nature of the “wet” form of the disease, there are no treatments for the vision loss experienced in the late stages of the “dry” form of the disease or for the late stages of the disease for those who experienced neovascularization but are now faced with a life of blindness from the condition. Research focus and investments are abundant in the early part of the disease when preventing progress of the disease is the goal. However, there is significant unmet medical need for those who have progressed beyond the benefit of these proposed drug interventions. We feel strongly that, while other companies focus on therapeutic interventions for AMD, our products should be considered complimentary interventions that serve to assist those patients who are in the end stages of the disease’s progression."
ThinkEquity will serve as sole underwriter.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ivanhoe Electric (IE) Prices 14.4M Share Offering at $11.75/sh
- Verrica Pharmaceuticals (VRCA) Holds Type A Meeting with FDA for VP-102 for Molluscum Contagiosum
- Ivanhoe Electric (IE) Announces 14.39M Share IPO at $11.75-$12.50/sh
Create E-mail Alert Related CategoriesCorporate News, IPOs
Related EntitiesThinkEquity, IPO
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!